logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Enhance R & D and protect intellectual property, petitions from the pharmaceutical industry to Europe

Source: actasanitaria.com

In order to highlight the priorities of the sector when there are just over seven months left for the next European elections, a manifesto, made public by the European Federation of the Pharmaceutical Industry (EFPIA), in which Farmaindustria is integrated, has collected as requests from the pharmaceutical industry to the future Europe to recognize the value of innovation through the measurement of health outcomes, maintain the strength of the current European model for the protection of intellectual and industrial property and turn Europe into a world power in clinical research through a framework that favors the development of clinical trials and public-private collaboration.

The document is based on three main concepts: ‘Health for all’, ‘European excellence’ and ‘Together we are stronger’. In the first case, the manifesto highlights how, thanks in large part to biomedical R & D led by the pharmaceutical industry in collaboration with health systems, and also to advances in prevention, diagnosis and treatment, large advances in the last decades in the fight against diseases, which means that the citizens of the European Union (EU) today live 30 years more than a century ago.

The document also defends the validity of vaccines as “the most effective method to prevent communicable diseases” and endorses the warnings of the World Health Organization (WHO) that the reluctance to vaccination is “a problem global complex that requires continuous monitoring “.

The second major objective of the manifesto is to join forces to try to position the EU as a “world leader in biomedical R & D”, on the basis that Europe is the second largest pharmaceutical market on a global scale, accounting for 22 percent of all sales of medicines, although “industrial and R & D investments are diverting from Europe to other more attractive places”.

Medical innovation
Faced with this reality, the signers of the document are committed to “keeping Europe at the forefront of medical innovation”, a field, that of R & D, in which the sector employs 115,000 people. For this, it indicates that it is necessary “to improve the position of Europe in the rapidity of the processing of innovative therapies that cover unmet health needs”, ensuring that the European Medicines Agency (EMA) has the flexibility and resources necessary to continue at the forefront of global regulatory excellence.

On the other hand, the pharmaceutical industry believes that the time has come to “move forward on a smart European agenda to promote investment and actively use Europe’s trade policy to promote European regulatory and industrial protection frameworks, as well as its approach to resistance antimicrobial “.

The third pillar of this manifesto is the promotion of public-private collaboration, which as reflected “is already achieving excellent results” in research through cooperation between public authorities, regulatory bodies, universities, hospitals, centers of research, patient associations and industry.

Farmaindustria notes that “this is essential to position Europe as the world’s leading center for clinical trials, as shown by projects such as the European Initiative for Innovative Medicines (IMI), the largest public-private health alliance in the world, with a total budget. of 5,000 million euros, half of which are provided by the European Commission and the other half by the pharmaceutical industry. ”

Distefar supports this type of requests whose aim is to turn Europe into a world power in clinical research.

Related entries

13 May, 2025

Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years


Leer más
12 May, 2025

Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.


Leer más
8 May, 2025

Spain, a European success story in clinical trials of new drugs


Leer más

Recent Posts

  • Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years
  • Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.
  • Spain, a European success story in clinical trials of new drugs
  • Joint position on the draft Medicines and Medical Devices Law
  • The global pharmaceutical industry had 12,700 drugs in development by 2024

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.